Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

[1]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[2]  Usha Chakravarthy,et al.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.

[3]  G. Ying,et al.  Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .

[4]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[5]  D. Roth,et al.  The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.

[6]  Quan Dong Nguyen,et al.  Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. , 2011, Ophthalmology.

[7]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[8]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[9]  G. Yancopoulos.  Clinical Application of Therapies Targeting VEGF , 2010, Cell.

[10]  N. Ferrara.  VEGF-A: a critical regulator of blood vessel growth. , 2009, European cytokine network.

[11]  T. Ianchulev,et al.  A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[12]  P. Rosenfeld,et al.  Predicted biological activity of intravitreal VEGF Trap , 2008, British Journal of Ophthalmology.

[13]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[14]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[15]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[16]  N. Congdon,et al.  Important causes of visual impairment in the world today. , 2003, JAMA.

[17]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[19]  N. Bressler.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[20]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[21]  Scott Carver,et al.  Cytokine traps: multi-component, high-affinity blockers of cytokine action , 2003, Nature Medicine.

[22]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[23]  S. Harding.  Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .